Stocks Health care ANVS
NYSE · Health careAnnovis Bio, Inc. (ANVS)
It posted a net loss of $49.5M. At June 30, 2026 it held $18.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Annovis Bio, Inc. does
Annovis Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ANVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$28.9M | -$1.40 | n/a |
| 2024 | $0 | -$24.6M | -$2.31 | n/a |
| 2023 | $0 | -$56.2M | -$6.23 | n/a |
| 2022 | $0 | -$25.3M | -$3.10 | n/a |
| 2021 | $0 | -$14.5M | -$1.90 | n/a |
| 2020 | $0 | -$5.5M | -$0.87 | n/a |
Latest SEC filings
What Annovis Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Proxy statement DEF 14A
- August 25, 2026Preliminary proxy statement PRE 14A
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026
- August 14, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 10, 2026Other event 8-K
- June 17, 2026
- May 20, 2026
- May 20, 2026
Questions about ANVS
What does Annovis Bio, Inc. do?
Annovis Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ANVS.
Is Annovis Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $49.5M.
When did Annovis Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 11, 2026.
Similar companies
Follow ANVS
Get an email when Annovis Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ANVS: get an email when it filesWhere the numbers come from
Financial figures are the values Annovis Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.